The latest Covid-19 vaccine award sees Glaxo and Sanofi score a $2.1bn windfall from the US government.
By signalling that its Covid-19 vaccine could cost just a few dollars Astra could seriously embarrass its competition.
Poziotinib unexpectedly succeeds in a lung cancer niche, but competition from Takeda must be tracked closely.
The UK big pharma is set to hand Japan’s Daiichi $1bn for rights to a second antibody-drug conjugate. Immunomedics watch out.
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
Big pharma pipelines are getting smaller, but novel medicines are being tested in more indications than ever before, a new analysis finds.
Those wanting to see whether the US government was right to give Novavax $1.6bn two weeks ago will have to wait a little longer.
The coronavirus vaccine race now features three front runners with clinical data, and at least one boasts impressive T-cell responses.
A small trial of inhaled interferon marks a 30-fold increase in Synairgen stock since January, but the endpoints warrant scrutiny.